Trademark Overview
On Tuesday, March 31, 2026, a trademark application was filed for LIRO THERAPEUTICS with the United States Patent and Trademark Office. The USPTO has given the LIRO THERAPEUTICS trademark a serial number of 79451797. The federal status of this trademark filing is NEW APPLICATION - RECORD INITIALIZED NOT ASSIGNED TO EXAMINER as of Thursday, June 11, 2026. This trademark is owned by Liro Therapeutics Pty Ltd. The LIRO THERAPEUTICS trademark is filed in the Advertising, Business and Retail Services and Computer & Software Services & Scientific Services categories with the following description:
Scientific services and related research services; scientific research; chemistry research; medical research; scientific and medical research and development; product development; scientific research and product development in the field of pharmaceuticals and biotechnology; research and development of pharmaceuticals for the treatment of cancer; medical research in the field of oncology; scientific research for medical purposes in the field of cancerous diseases; laboratory research and analysis; pharmaceutical research; drug development; pharmaceutical drug development services; development of pharmaceutical preparations and medicines; assessing the safety and efficiency relating to pharmaceuticals; laboratory testing; quality control; advisory and consultancy services in relation to the foregoing; providing information, including online, in regard to all the aforesaid services.
Business management, organisation and administration; strategic development, business management and implementation of business plans for the development and commercialisation of drugs and therapies; business management services relating to commercialisation of technology, processes and products; promoting public awareness in the field of cancer research; advisory, consultancy, business management and organisational services in relation to the foregoing; providing information, including online, in regard to all the aforesaid services.